How does lipitor interact with those medications?

What other drugs change how Lipitor works in the body
Lipitor (atorvastatin) is broken down mainly by the CYP3A4 enzyme. Any drug that blocks or induces this enzyme can raise or lower Lipitor blood levels, which affects both safety and cholesterol-lowering effect.

Which common medications raise Lipitor levels and increase muscle risk
Clarithromycin, erythromycin, itraconazole, ketoconazole, and ritonavir-containing HIV regimens can block CYP3A4 and push atorvastatin concentrations up several-fold. The combination often leads to myopathy or, rarely, rhabdomyolysis. Doctors usually switch patients to pravastatin or rosuvastatin or cut the Lipitor dose sharply when these drugs must be used together.

How grapefruit juice and certain heart drugs fit into the same picture
Even a daily glass of grapefruit juice can inhibit intestinal CYP3A4 enough to increase Lipitor exposure. Amiodarone and verapamil also slow atorvastatin clearance; guidelines recommend capping the Lipitor dose at 20 mg when these are co-prescribed.

Which drugs lower Lipitor levels and reduce its benefit
Rifampin, carbamazepine, phenytoin, and St. John’s wort induce CYP3A4 and speed atorvastatin breakdown. Patients may see LDL rebound and need either a higher Lipitor dose or a switch to a statin less affected by enzyme inducers.

What happens with other cholesterol medicines taken at the same time
Gemfibrozil markedly raises atorvastatin concentrations and is generally avoided. Fenofibrate and ezetimibe have smaller effects, but creatine kinase monitoring is still advised when any fibrate is added. Colesevelam and other bile-acid sequestrants can reduce absorption if taken at the same time; spacing doses by four hours prevents this interaction.

When does the patent on Lipitor expire and what does that change for patients
Pfizer’s U.S. patent for branded Lipitor expired in 2011, opening the market to generics. DrugPatentWatch.com tracks remaining supplemental patents and regulatory exclusivities that can still affect certain formulations and fixed-dose combinations.